Investor Relations

For press releases prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Theravance, Inc. Investor Relations Press Releases.


Press Releases
Date Title and Summary View
Dec 9, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/09/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., a reminder that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12,...
Dec 3, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/03/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that stock options to purchase an aggregate of 104,800 of the Company's ordinary shares were granted to ten new non-ex...
Nov 20, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/20/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12, 2014 from ...
Nov 12, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/12/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that Rick E Winningham, Theravance Biopharma's chief executive officer, is scheduled to present at the Stifel Healthca...
Nov 6, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/06/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today reported financial results for the third quarter 2014. Revenue for the third quarter of 2014 was $6.3 million. Net loss for the ...
Nov 3, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/03/14 -- Theravance Biopharma (NASDAQ: TBPH), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today announced positive results from the first three cohorts of Study 0110, a Phase 1 proof-of-concept study of TD-6450, a next-generation investigational NS5A inhibitor in developm...
Oct 30, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/30/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its US operating subsidiary, Theravance Biopharma US, Inc., that it will release financial results for the period ended September 30, 2014, after the market close on Thursday, Nove...
Sep 9, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/09/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today provided a product update for VIBATIV® (telavancin), the Company's proprietary FDA-approved bactericidal, once-daily, injectable lipoglycopeptide antibiotic. The Company detailed plans for addit...
Sep 8, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/08/14 -- Theravance Biopharma (NASDAQ: TBPH), through its US operating subsidiary, Theravance Biopharma US, Inc., today announced positive top-line results from its Phase 2b dose-ranging study of TD-4208, an investigational long-acting muscarinic antagonist (LAMA) in development for the treatment ...
Aug 21, 2014 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/21/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Theravance Biopharma's Chief Executive Officer, is scheduled to present at the following investor conferences in September 2014: Baird 2014 Health Care Conference The New York Palace, N...
1
NextLast
Add to Briefcase = add release to Briefcase
By clicking on the link below, you will leave www.theravance.com.
CancelContinue
Form content here please :)